Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth |
---|
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1210 | Amputation of Bilateral Feet | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1211 | Amputation of Bilateral Feet | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1212 | Amputation of Left Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1213 | Amputation of Left Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1214 | Amputation of Left Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1215 | Amputation of Right Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1216 | Amputation of Right Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1217 | Amputation of Right Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1218 | Amputation of Unspecified Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1219 | Amputation of Unspecified Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.122.11.1003 | Ambulatory | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.122.12.1003 | Ambulatory | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1220 | Foot Assessment With Abnormal Result or Finding | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1221 | Foot Assessment With Abnormal Result or Finding | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1222 | Acquired Absence of Bilateral feet | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1223 | Acquired Absence of Bilateral feet | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1224 | Acquired Absence of Left Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1225 | Acquired Absence of Left Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1226 | Acquired Absence of Left Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1227 | Acquired Absence of Right Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1228 | Acquired Absence of Right Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1229 | Acquired Absence of Right Foot | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1230 | Lower Body Fractures Excluding Ankle and Foot | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1231 | Malignant Neoplasms of Lower and Unspecified Limbs | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1232 | Mechanical Complications Excluding Upper Body | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1233 | Partial Arthroplasty of Hip | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1234 | Partial Arthroplasty of Hip | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1235 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | | | 2025-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1236 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1237 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1238 | Primary THA Procedure | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1239 | Foot Ulcer | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1240 | Foot Ulcer | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1241 | Foot Ulcer | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1242 | Referral for Foot Care | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1243 | Therapeutic Footwear | active | | | 2023-08 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1244 | Foot Deformity | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1245 | Foot Deformity | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1246 | Foot Deformity | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1247 | Megestrol Medications | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1248 | Meperidine Medications | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1249 | Potentially Harmful Antidepressants for Older Adults | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.125.11.1004 | Fluoride Varnish Application for Children | active | | | 2024-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.125.11.1007 | Dental Caries | active | | | 2025-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.125.11.1009 | Dental Caries | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.125.11.1010 | Clinical Oral Evaluation | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.125.11.1011 | Fluoride Varnish Application for Children | active | | | 2024-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.125.12.1002 | Fluoride Varnish Application for Children | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.125.12.1003 | Clinical Oral Evaluation | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.125.12.1004 | Dental Caries | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1250 | Potentially Harmful Antihistamines for Older Adults | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1251 | Potentially Harmful Antiparkinsonian Agents for Older Adults | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1252 | Potentially Harmful Barbiturates for Older Adults | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1253 | Potentially Harmful Estrogens for Older Adults | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1254 | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1255 | Potentially Harmful Pain Medications for Older Adults | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1256 | Potentially Harmful Skeletal Muscle Relaxants for Older Adults | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1257 | Potentially Harmful Sulfonylureas for Older Adults | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1258 | Substance Use Disorder Long Acting Medication | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1259 | Substance Use Disorder Short Acting Medication | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1260 | Viloxazine | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1266 | Diabetic Retinopathy Severity Level | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1272 | Diabetes | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1273 | Diabetes | active | | | 2025-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.195.11.1003 | Counseling for Nutrition | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.195.11.1004 | Counseling for Nutrition | active | | | 2023-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.195.12.1003 | Counseling for Nutrition | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1001 | Antibiotic Medications for Pharyngitis | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1078 | Nifedipine Medications | active | | | 2022-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1080 | Contraceptive Medications | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1109 | Meperidine Medications | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1129 | Desiccated Thyroid Medications | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1143 | Isotretinoin | active | | | 2022-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1167 | Dipyridamole Medications | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1205 | Leucovorin | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1211 | Aspirin and Other Antiplatelets | active | | | 2024-06 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1212 | DTaP Vaccine | active | | | 2024-11 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1214 | Hepatitis A Vaccine | active | | | 2018-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1216 | Hepatitis B Vaccine | active | | | 2025-04 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1220 | Child Influenza Vaccine | active | | | 2022-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1222 | Inactivated Polio Vaccine (IPV) | active | | | 2021-09 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1228 | Pneumococcal Conjugate Vaccine | active | | | 2023-11 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1232 | Rotavirus Vaccine (3 dose schedule) | active | | | 2018-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1234 | Varicella Zoster Vaccine (VZV) | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1235 | Measles, Mumps and Rubella (MMR) Vaccine | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1252 | Guanfacine Medications | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1255 | Megestrol Medications | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1256 | Meprobamate Medications | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1266 | Aromatase Inhibitors | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1267 | Glucocorticoids (oral only) | active | | | 2024-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1481 | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1482 | Potentially Harmful Antiinfectives for Older Adults | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1517 | Dementia Medications | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1530 | Antidepressant Medication | active | | | 2024-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.11.1532 | Potentially Harmful Antipsychotics for Older Adults | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1001 | Antibiotic Medications for Pharyngitis | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1080 | Contraceptive Medications | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1143 | Isotretinoin | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1170 | Varicella Zoster Vaccine (VZV) | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1205 | Leucovorin | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1211 | Aspirin and Other Antiplatelets | active | | | 2024-06 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1213 | Antidepressant Medication | active | | | 2021-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1214 | DTaP Vaccine | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1215 | Hepatitis A Vaccine | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1216 | Hepatitis B Vaccine | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1218 | Child Influenza Vaccine | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1219 | Inactivated Polio Vaccine (IPV) | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1221 | Pneumococcal Conjugate Vaccine | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1223 | Rotavirus Vaccine (3 dose schedule) | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1224 | Measles, Mumps and Rubella (MMR) Vaccine | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1265 | Aromatase Inhibitors | active | | | 2018-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1266 | Glucocorticoids (oral only) | active | | | 2018-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1480 | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1481 | Potentially Harmful Antiinfectives for Older Adults | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1510 | Dementia Medications | active | | | 2019-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1522 | Potentially Harmful Benzodiazepines for Older Adults | active | | | 2022-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.196.12.1523 | Potentially Harmful Antipsychotics for Older Adults | active | | | 2022-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1005 | Bilateral Mastectomy | active | | | 2024-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1009 | Primary THA Procedure | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1015 | Flexible Sigmoidoscopy | active | | | 2023-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1016 | Flexible Sigmoidoscopy | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1017 | Flexible Sigmoidoscopy | active | | | 2024-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1020 | Fecal Occult Blood Test (FOBT) | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1023 | Group A Streptococcus Test | active | | | 2024-11 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1024 | HbA1c Laboratory Test | active | | | 2023-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1026 | Hysterectomy with No Residual Cervix | active | | | 2023-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1027 | Hysterectomy with No Residual Cervix | active | | | 2024-11 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1035 | Total Colectomy | active | | | 2024-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1036 | Total Colectomy | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1055 | XRay Study | active | | | 2022-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1061 | Gastric Bypass Surgery | active | | | 2020-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1062 | Gastric Bypass Surgery | active | | | 2018-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1080 | Primary THA Procedure | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1084 | History of bilateral mastectomy | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1085 | History of bilateral mastectomy | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1086 | Status Post Left Mastectomy | active | | | 2018-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1087 | Status Post Right Mastectomy | active | | | 2018-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1089 | Unilateral Mastectomy, Unspecified Laterality | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1090 | Unilateral Mastectomy, Unspecified Laterality | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1091 | Status Post Left Mastectomy | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1092 | Status Post Right Mastectomy | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1096 | Major Transplant | active | | | 2021-09 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1097 | Major Transplant | active | | | 2021-08 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1132 | Unilateral Mastectomy Left | active | | | 2021-10 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1133 | Unilateral Mastectomy Right | active | | | 2021-10 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1134 | Hysterectomy with No Residual Cervix | active | | | 2023-09 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1135 | Hysterectomy with No Residual Cervix | active | | | 2020-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1140 | Bilateral Mastectomy | active | | | 2019-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1143 | Total Colectomy | active | | | 2019-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1144 | Unilateral Mastectomy Left | active | | | 2019-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1145 | Unilateral Mastectomy Right | active | | | 2019-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.11.1148 | Palliative Intervention | active | | | 2023-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1005 | Bilateral Mastectomy | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1006 | Primary THA Procedure | active | | | 2023-08 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1010 | Flexible Sigmoidoscopy | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1011 | Fecal Occult Blood Test (FOBT) | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1012 | Group A Streptococcus Test | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1013 | HbA1c Laboratory Test | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1014 | Hysterectomy with No Residual Cervix | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1019 | Total Colectomy | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1034 | XRay Study | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1050 | Gastric Bypass Surgery | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1068 | History of bilateral mastectomy | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1069 | Status Post Left Mastectomy | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1070 | Status Post Right Mastectomy | active | | | 2017-12 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1071 | Unilateral Mastectomy, Unspecified Laterality | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1075 | Major Transplant | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1133 | Unilateral Mastectomy Left | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1134 | Unilateral Mastectomy Right | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135 | Palliative Care Intervention | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.11.1064 | Anaphylactic Reaction to DTaP Vaccine | active | | | 2022-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.11.1100 | Malabsorption Syndromes | active | | | 2023-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.11.1102 | Malabsorption Syndromes | active | | | 2022-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.11.1105 | Intussusception | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.11.1106 | Intussusception | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.11.1107 | Influenza Virus LAIV Vaccine | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.11.1108 | Influenza Virus LAIV Vaccine Administered | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.12.1031 | Anaphylactic Reaction to DTaP Vaccine | active | | | 2022-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.12.1050 | Malabsorption Syndromes | active | | | 2024-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.199.12.1056 | Intussusception | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1004.2446 | Lower Extremity Visual Inspection Test | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1004.2447 | Pedal Pulse Result or Finding | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1004.2448 | Monofilament Test Result or Finding | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1004.2449 | Monofilament Tests | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1004.2450 | Lower Extremity Neurological Assessment Result or Finding | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1004.2451 | Lower Extremity Neurological Tests | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1004.2452 | Lower Extremity Visual Inspection Result or Finding | active | | | 2023-07 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1004.2616 | Autonomous Eye Exam Result or Finding | active | | | 2025-01 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.1577 | Pharmacologic Therapy for Hypertension | active | | | 2021-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1036 | Chronic Kidney Disease, Stage 5 | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1037 | Chronic Kidney Disease, Stage 5 | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1049 | Patient Provider Interaction | active | | | 2020-03 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1058 | Psych Visit for Family Psychotherapy | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1063 | Occupational Therapy Evaluation | active | | | 2017-08 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1067 | Dementia and Mental Degenerations | active | | | 2024-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1068 | Dementia and Mental Degenerations | active | | | 2025-02 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1069 | Standardized Tools for Assessment of Cognition | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1071 | Radiation Treatment Management | active | | | 2017-08 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1072 | Radiation Treatment Management | active | | | 2017-05 | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.526.2.1073 | Standardized Pain Assessment Tool | active | | | 2017-05 | hl7 |